Beginning Cash: The amount of cash reported by the company on its previous statement.
AgomAb Therapeutics NV (AGMB) had Beginning Cash of $100.48M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$300.54M |
|
$0.52M |
|
$37.72M |
|
$338.26M |
|
$23.34M |
|
$1.06M |
|
$6.37M |
|
$29.70M |
|
$308.55M |
|
$275.16M |
|
$308.55M |
|
-- |
|
| Cash Flow Statement Financials | |
$-34.78M |
|
-- |
|
$191.95M |
|
|
Beginning Cash |
$100.48M |
$257.64M |
|
$157.16M |
|
$2.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|